Skip to main content

Merck & Co., Inc. stock price and financials

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$147.76+0.55%Close 13 Nov 2026
EV / EBITDA
14.45
Beta · 1 year
0.19
Return · 1 year
+61.6%
52-week range$90.90 — $156.92

Share price close 16 Nov 2026

+1.0%1 monthHigh $150.36Low $140.61
$140$142.5$145$147.5$150$152.5Q3 FY2026 report filed 4 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+31.7%6 monthsHigh $156.45Low $112.56
$100$120$140$160Q2 FY2026 report filed 7 Aug 2026Q3 FY2026 report filed 4 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+39.3%year to dateHigh $156.45Low $106.45
$100$120$140$160Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 4 May 2026Q2 FY2026 report filed 7 Aug 2026Q3 FY2026 report filed 4 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+57.8%1 yearHigh $156.45Low $92.86
$80$100$120$140$160Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 4 May 2026Q2 FY2026 report filed 7 Aug 2026Q3 FY2026 report filed 4 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+44.7%3 yearsHigh $156.45Low $73.47
$50$75$100$125$150$175Q4 FY2023 report filed 26 Feb 2024Q1 FY2024 report filed 3 May 2024Q2 FY2024 report filed 5 Aug 2024Q3 FY2024 report filed 6 Nov 2024Q4 FY2024 report filed 25 Feb 2025Q1 FY2025 report filed 2 May 2025Q2 FY2025 report filed 5 Aug 2025Q3 FY2025 report filed 5 Nov 2025Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 4 May 2026Q2 FY2026 report filed 7 Aug 2026Q3 FY2026 report filed 4 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+148%10 yearsHigh $156.45Low $50.92
$50$100$150$200Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Merck & Co., Inc. reported revenue of $65.0 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 1.3% from fiscal 2024. Net income was $18.3 billion and diluted earnings per share $7.28.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $18.1 billion, up 4.7% from a year earlier.

Figures from Merck & Co., Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 4 Nov 2026.

Revenue FY2025
$65.01B+1.3%
Net income
$18.25B+6.6%
Diluted EPS
$7.28+8.0%
Gross margin
74.8%−1.5 pts
Free cash flow
$12.36B−31.7%
Net debt
$35.93B+46.2%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$20B$40B$60B$80BRevenue, FY16: $39.81BNet income, FY16: $3.92BFY16Revenue, FY17: $40.12BNet income, FY17: $2.39BFY17Revenue, FY18: $42.29BNet income, FY18: $6.22BFY18Revenue, FY19: $39.12BNet income, FY19: $9.84BFY19Revenue, FY20: $41.52BNet income, FY20: $7.07BFY20Revenue, FY21: $48.7BNet income, FY21: $13.05BFY21Revenue, FY22: $59.28BNet income, FY22: $14.52BFY22Revenue, FY23: $60.12BNet income, FY23: $365MFY23Revenue, FY24: $64.17BNet income, FY24: $17.12BFY24Revenue, FY25: $65.01BNet income, FY25: $18.25BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 4 Nov 2026 · Full results →

Revenue
$18.09B+4.7% on a year
Gross margin
72.9%−4.7 pts on a year
Operating income
$6.11B−13.7% on a year
Net income
$5.07B−12.4% on a year
Diluted EPS
$2.04−12.1% on a year
Free cash flow
$5.52B−19.3% on a year

Comparable companies All of Health Care →

Merck & Co., Inc. beside the other S&P 500 members in Pharmaceuticals, by market value.

Merck & Co., Inc. and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Merck & Co.MRK—+0.6%+61.6%———
Eli LillyLLY$1.37T+1.1%+41.8%+45.5%31.9%49.6
Johnson & JohnsonJNJ$686.1B+0.8%+47.0%+7.8%16.2%42.6
Bristol Myers SquibbBMY$128.5B+1.8%+29.2%+4.2%18.5%13.9
PfizerPFE—+0.2%+11.7%———
ViatrisVTRS—+0.7%+89.1%———
ZoetisZTS—+1.0%−30.9%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%50%100%74.8%34.5%28.1%FY16FY19FY22FY25

Merck & Co., Inc. revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Merck & Co., Inc. revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Pharmaceutical$42.75B$52.01B+21.6%$53.58B+3.0%$57.40B+7.1%$58.14B+1.3%
Animal Health$5.57B$5.55B−0.3%$5.63B+1.4%$5.88B+4.5%$6.35B+8.1%
Corporate, Non-Segment$382.0M$1.73B+352%$907.0M−47.5%$891.0M−1.8%$515.0M−42.2%
Total revenue$48.70B$59.28B$60.12B$64.17B$65.01B

By region

Merck & Co., Inc. revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$22.43B$27.21B+21.3%$28.48B+4.7%$32.28B+13.3%$36.51B+13.1%
Europe, Middle East and Africa$13.34B$14.49B+8.6%$13.25B−8.5%$14.04B+5.9%$14.58B+3.8%
Latin America$2.21B$2.58B+17.0%$3.09B+19.5%$3.46B+12.1%$3.41B−1.4%
Asia Pacific (other than Japan and China)$2.41B$3.61B+50.1%$3.23B−10.8%$3.06B−5.2%$2.98B−2.5%
Other$1.22B$2.57B+110%$2.10B−18.1%$2.56B+21.6%$2.88B+12.5%
Japan$2.73B$3.63B+33.1%$3.16B−12.8%$3.28B+3.7%$2.71B−17.3%
China$4.38B$5.19B+18.6%$6.80B+31.0%$5.49B−19.2%$1.94B−64.7%
Total revenue$48.70B$59.28B$60.12B$64.17B$65.01B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Merck & Co., Inc. income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$39.81B$40.12B$42.29B$39.12B$41.52B$48.70B$59.28B$60.12B$64.17B$65.01B
Revenue growth+0.8%+0.8%+5.4%−7.5%+6.1%+17.3%+21.7%+1.4%+6.7%+1.3%
Gross profit$25.78B$27.21B$28.79B$27.11B$27.90B$35.08B$41.87B$43.99B$48.98B$48.63B
Operating income$5.35B$7.28B$9.47B$8.06B$6.69B$14.69B$17.41B$3.04B$21.21B$22.42B
Net income$3.92B$2.39B$6.22B$9.84B$7.07B$13.05B$14.52B$365.0M$17.12B$18.25B
Diluted EPS$1.41$0.87$2.32$3.81$2.78$5.14$5.71$0.14$6.74$7.28
Gross margin64.8%67.8%68.1%69.3%67.2%72.0%70.6%73.2%76.3%74.8%
Operating margin13.4%18.1%22.4%20.6%16.1%30.2%29.4%5.0%33.0%34.5%
Net margin9.8%6.0%14.7%25.2%17.0%26.8%24.5%0.6%26.7%28.1%

Cash flow

Merck & Co., Inc. cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$10.38B$6.45B$10.92B$8.88B$7.62B$14.11B$19.09B$13.01B$21.47B$16.47B
Capital expenditure$1.61B$1.89B$2.62B$3.37B$4.43B$4.45B$4.39B$3.86B$3.37B$4.11B
Free cash flow$8.76B$4.56B$8.31B$5.51B$3.19B$9.66B$14.71B$9.14B$18.10B$12.36B

Balance sheet and shares

Merck & Co., Inc. balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$6.51B$6.09B$7.96B$9.68B$8.05B$8.10B$12.69B$6.84B$13.24B$14.56B
Total debt$24.57B$24.35B$25.10B$27.30B$33.43B$34.63B$31.99B$36.31B$38.26B$50.49B
Shareholders' equity$40.09B$34.34B$26.70B$25.91B$25.32B$38.18B$45.99B$37.58B$46.31B$52.61B
Diluted shares2.8B2.7B2.7B2.6B2.5B2.5B2.5B2.5B2.5B2.5B
Dividends per share$1.85$1.89$1.99$2.26$2.48$2.64$2.80$2.96$3.12$3.28

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Merck & Co., Inc. quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$15.62B$15.53B$15.81B$17.28B$16.40B$16.29B$16.61B$18.09B
Revenue, year on year+6.8%−1.6%−1.9%+3.7%+5.0%+4.9%+5.1%+4.7%
Gross margin75.5%78.0%77.5%77.7%66.2%74.2%73.5%72.9%
Operating income$4.50B$6.22B$5.30B$7.07B$3.83B−$3.06B−$158.0M$6.11B
Net income$3.74B$5.08B$4.43B$5.79B$2.96B−$4.24B−$1.33B$5.07B
Diluted EPS$1.48$2.01$1.76$2.32$1.19−$1.72−$0.54$2.04
Free cash flow$2.51B$1.17B$2.53B$6.83B$1.82B$2.93B$4.48B$5.52B

Operating KPIs

The operating figures Merck & Co., Inc. reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Merck & Co., Inc. operating KPIs
KPILatestPeriodChange on a yearRecent periods
Keytruda revenue$7.8Bquarter to 30 Sep 2026down 4.6%
Gardasil/Gardasil 9 revenue$2.0Bquarter to 30 Sep 2026up 14.1%
Livestock revenue$1.0Bquarter to 30 Sep 2026up 2.4%
Keytruda Qlex revenue$830.0Mquarter to 30 Sep 2026—
ProQuad/M-M-R II/Varivax revenue$730.0Mquarter to 30 Sep 2026up 6.7%
Winrevair revenue$694.0Mquarter to 30 Sep 2026up 92.8%
Companion Animal revenue$628.0Mquarter to 30 Sep 2026up 6.1%
Lynparza alliance revenue$352.0Mquarter to 30 Sep 2026down 7.1%
Prevymis revenue$347.0Mquarter to 30 Sep 2026up 30.5%
Welireg revenue$307.0Mquarter to 30 Sep 2026up 56.6%
Lenvima alliance revenue$287.0Mquarter to 30 Sep 2026up 11.2%
Capvaxive revenue$263.0Mquarter to 30 Sep 2026up 7.8%
RotaTeq revenue$196.0Mquarter to 30 Sep 2026down 3.9%
Vaxneuvance revenue$195.0Mquarter to 30 Sep 2026down 13.7%
Janumet revenue$194.0Mquarter to 30 Sep 2026down 20.2%
Januvia revenue$186.0Mquarter to 30 Sep 2026down 51.3%
Ohtuvayre revenue$184.0Mquarter to 30 Sep 2026—
Reblozyl alliance revenue$177.0Mquarter to 30 Sep 2026up 30.1%
Bridion revenue$144.0Mquarter to 30 Sep 2026down 67.2%
Adempas/Verquvo alliance revenue$118.0Mquarter to 30 Sep 2026up 5.4%
Zerbaxa revenue$90.0Mquarter to 30 Sep 2026up 11.1%
Adempas revenue$78.0Mquarter to 30 Sep 2026down 4.9%
Delstrigo revenue$67.0Mquarter to 30 Sep 2026down 13.0%
Isentress/Isentress HD revenue$52.0Mquarter to 30 Sep 2026down 36.6%
Belsomra revenue$49.0Mquarter to 31 Dec 2025up 8.9%
Pifeltro revenue$43.0Mquarter to 31 Dec 2025up 7.5%
Pneumovax 23 revenue$42.0Mquarter to 31 Dec 2025down 44.0%
Lagevrio revenue$17.0Mquarter to 30 Sep 2026down 87.7%
Dificid revenue$14.0Mquarter to 30 Sep 2026down 67.4%
Koselugo alliance revenue$13.0Mquarter to 30 Sep 2026down 93.9%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Merck & Co., Inc.'s revenue in fiscal 2025?

$65.0 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Merck & Co., Inc.'s net income in fiscal 2025?

$18.3 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Merck & Co., Inc.'s diluted earnings per share in fiscal 2025?

$7.28 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Merck & Co., Inc.'s gross margin?

74.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Merck & Co., Inc.'s operating margin?

34.5% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Merck & Co., Inc. generate in fiscal 2025?

$12.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Merck & Co., Inc.'s revenue come from?

In fiscal 2025, by segment: Pharmaceutical $58.14B (89%), Animal Health $6.35B (9.8%), Corporate, Non-Segment $515.0M (0.8%), out of $65.01B in all, as stated in its annual report.

In the terminal

Twenty years of Merck & Co., Inc.'s figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans